Cashu | News | TVTX

HomeWatchlistNewsSignalsPicks

DJI

+0.77%

SPX

+0.83%

IXIC

+0.98%

FTSE

+0.42%

N225

+0.73%

AXJO

+0.49%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Latest Travere Therapeutics News

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari

Feature Image for interests on Biotech, Government, Health Care, Healthcare from benzinga.com

Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings)

Earnings Preview: Travere Therapeutics

about 1 month ago

Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews

Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ARMISTICE CAPITAL, LLC Acquires New Stake in CNS Pharmaceuticals Inc

Feature Image for interests on Article, Cnsp, Gurufocus, Gurufocus News from gurufocus.com

businesswire.com

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Feature Image for interests on Healthcare, Stock, Technology, Unknown Sector from businesswire.com

Cramer's Lightning Round: Hold on to Palantir

Feature Image for interests on Business, Healthcare, Industrials, Investment Strategy from cnbc.com

finance.yahoo.com

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy

Feature Image for interests on Csl Vifor, Filspari, Healthcare, Kidney Disease from finance.yahoo.com

finance.yahoo.com

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy

Feature Image for interests on Csl Vifor, Emmanuelle Lecomte Brisset, Healthcare, Iga Nephropathy from finance.yahoo.com

Latest Cashu News

Travere Therapeutics Secures FDA Approval for Filspari, Advancing Nephrology Treatment

FDA Approves Travere Therapeutics' Filspari for IgA Nephropathy Treatment, Enhancing Patient Care

Travere Therapeutics Secures FDA Approval for Filspari in IgA Nephropathy Treatment

Stocks

Health Care

tvtx

Travere Therapeutics

NASDAQ: TVTX

+1.55 (+7.90%)

21.16

USD

At close at Sep 04, 20:39 UTC